An investigational vaccine called ChAdOx1 MERS protected two groups of rhesus macaques from disease caused by Middle East respiratory syndrome coronavirus (MERS-CoV). MERS-CoV is a relative of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19).
National Institutes of Health scientists and colleagues are pursuing similar studies with ChAdOx1 SARS2, a vaccine candidate against SARS-CoV-2. They posted their results with ChAdOx1 MERS on a preprint server. The findings are not yet peer-reviewed but are being shared to assist the public health response to COVID-19.
ChAdOx1 MERS, which uses a replication-deficient chimpanzee adenovirus to deliver a MERS-CoV protein in recipients, also worked against six different strains of MERS-CoV when tested in mice as a single vaccination. Scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) at Rocky Mountain Laboratories in Hamilton, Mont., led the project. Collaborators work at the University of Oxford in the United Kingdom; researchers at the University of Oxford Jenner Institute developed the ChAdOx1 vaccine technology.
Human cases of MERS-CoV were first reported in Saudi Arabia in 2012; dromedary camels are also infected with the virus and likely transmit it to people. MERS-CoV causes disease deep in the lungs, leading to pneumonia among infected individuals. Through January 2020, the World Health Organization had received reports of 2,519 MERS-CoV cases and 866 deaths in 27 countries.
Read more at NIH
- Germany COVID-19: ‘The infection numbers have sunk significantly’, Outbreak ‘under control’
- COVID-19: Contact tracing smartphone app warns of exposure while protecting privacy
- Universal vaccine for Ebola viruses: May fight all four virus species that infect humans according to early preclinical tests
- Remdesivir improved majority of patients hospitalized with severe COVID-19
- Philippines COVID-19: 200 additional cases reported, Testing protocol explained
- Malaysia reports 80 percent of COVID-19 deaths had chronic diseases
- Japan: Influenza antiviral drug Avigan production ramped up for COVID-19